Nektar Financial Statements From 2010 to 2024
NKTR Stock | USD 0.93 0.04 4.49% |
Gross Profit 70.4 M | Market Capitalization 171.5 M | Enterprise Value Revenue 1.2051 | Revenue 90.1 M | Earnings Share (1.45) |
Check Nektar Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Nektar main balance sheet or income statement drivers, such as Depreciation And Amortization of 7.4 M, Interest Expense of 23.9 M or Total Revenue of 162.3 M, as well as many exotic indicators such as Price To Sales Ratio of 1.13, Dividend Yield of 0.001 or Operating Cycle of 170. Nektar financial statements analysis is a perfect complement when working with Nektar Therapeutics Valuation or Volatility modules.
Nektar | Select Account or Indicator |
Nektar Therapeutics Balance Sheet | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Nektar Therapeutics Income Statement | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Nektar Therapeutics Cash Flow Statement | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Ratios | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Nektar Fundamental Market Drivers
Cash And Short Term Investments | 303.6 M |
Nektar Upcoming Events
27th of February 2024 Upcoming Quarterly Report | View | |
14th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
27th of February 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
About Nektar Therapeutics Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Nektar Therapeutics income statement, its balance sheet, and the statement of cash flows. Nektar Therapeutics investors use historical funamental indicators, such as Nektar Therapeutics's revenue or net income, to determine how well the company is positioned to perform in the future. Although Nektar Therapeutics investors may use each financial statement separately, they are all related. The changes in Nektar Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Nektar Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Nektar Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Nektar Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last Reported | Projected for 2024 | ||
Current Deferred Revenue | 104.7 K | 99.4 K | |
Total Revenue | 90.1 M | 162.3 M | |
Cost Of Revenue | 36.6 M | 26.8 M | |
Ebit Per Revenue | (1.52) | (1.60) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Nektar Therapeutics Correlation against competitors. To learn how to invest in Nektar Stock, please use our How to Invest in Nektar Therapeutics guide.You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Complementary Tools for Nektar Stock analysis
When running Nektar Therapeutics' price analysis, check to measure Nektar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nektar Therapeutics is operating at the current time. Most of Nektar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nektar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nektar Therapeutics' price. Additionally, you may evaluate how the addition of Nektar Therapeutics to your portfolios can decrease your overall portfolio volatility.
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
CEOs Directory Screen CEOs from public companies around the world | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |
Is Nektar Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nektar Therapeutics. If investors know Nektar will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nektar Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.45) | Revenue Per Share 0.474 | Quarterly Revenue Growth 0.085 | Return On Assets (0.15) | Return On Equity (1.11) |
The market value of Nektar Therapeutics is measured differently than its book value, which is the value of Nektar that is recorded on the company's balance sheet. Investors also form their own opinion of Nektar Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Nektar Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nektar Therapeutics' market value can be influenced by many factors that don't directly affect Nektar Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nektar Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Nektar Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nektar Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.